Otsuka Holdings Co Ltd (Otsuka) is a diversified healthcare company engaged in the development, manufacturing, and sale of pharmaceuticals, nutraceuticals, consumer products, and other related businesses. The company operates through a network of subsidiaries and affiliated companies, focusing on medical-related, nutraceutical-related, consumer-related, and other businesses such as warehousing, transportation, liquid crystal and spectroscopy, and chemicals.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Otsuka's R&D activities focus on developing novel pharmaceutical and nutraceutical products. The company focuses on research and development in key areas such as psychiatry/neurology, oncology, cardiovascular/renal medicine, and autoimmune diseases, targeting unmet medical needs. The company aims to enhance its pipeline in these areas and increase the likelihood of development success. It is also committed to developing systematic solutions for optimizing healthcare and aims for sustainable evolution and growth by strengthening its drug discovery platform and diversifying drug discovery modalities through alliances, open innovation, and collaboration with venture capital. The company leverages its expertise in the renal field to advance clinical development for autoimmune diseases and strengthen its pipeline through acquisitions and alliances. Additionally, Otsuka is actively promoting research and development to address unmet needs in the autoimmune disease field, where treatment options are limited. The company operates R&D and clinical development facilities in Japan, Korea, China, Germany, South Korea, the US, and the UK. In the Pharmaceutical business, the company is committed to advancing R&D initiatives in psychiatry and neurology, leveraging small and large-molecule compound technologies and digital tools. Additionally, it focuses on maximizing business value in oncology through proprietary drug discovery platforms and collaborations with startups. The company's Nutraceutical business conducts R&D in various areas such as clinical exercise, intestinal immunity, and medical foods. Research focuses on sports nutrition, mucosal immunity enhancement, and clinical nutrition to improve product value and disseminate scientific information. It is also expanding into the autoimmune space, with a promising pipeline for autoimmune diseases in the renal area. Otsuka conducts its research and development activities primarily in Japan and the US. The company outsources clinical development of new drugs to Otsuka Pharmaceutical D&C Inc. in the US, while Taiho Pharmaceutical Co Ltd outsources its clinical development work to Taiho Oncology Inc. These units are responsible for managing the company's R&D activities, focusing on the development of innovative products and solutions. A few of the pipeline products in Phase III clinical trials include EB-1020 for the treatment of attention-deficit hyperactivity disorder; TAS-205 for Duchenne muscular dystrophy; TAS-115 for osteosarcoma; SEP-363856 for the treatment of Schizophrenia/Major depressive disorder/Generalized anxiety disorder; and OPC-167832 for the treatment of Tuberculosis, among others. In FY2025, the company spent JPY352,838 million on its R&D activities, which as a percentage of revenue stood at 14.3%, and grew 12.3% YoY.